NASDAQ:RENB Renovaro (RENB) Stock Price, News & Analysis → Proof that the Musk/Bezos rivalry is about to hit a new level (From InvestorPlace) (Ad) Free RENB Stock Alerts $1.26 -0.20 (-13.70%) (As of 01:45 PM ET) Add Compare Share Share Today's Range$1.25▼$1.4850-Day Range$1.47▼$3.2352-Week Range$0.39▼$5.25Volume95,911 shsAverage Volume296,201 shsMarket Capitalization$181.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Renovaro alerts: Email Address Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About Renovaro Stock (NASDAQ:RENB)Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.Read More RENB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RENB Stock News HeadlinesMay 4, 2024 | americanbankingnews.comRenovaro (NASDAQ:RENB) Trading 0.7% Higher April 30, 2024 | globenewswire.comTransforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on FragmentomicsMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…April 24, 2024 | globenewswire.comRenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics PartnershipApril 20, 2024 | uk.investing.comRenovaro appoints distinguished professor as new Chair of Scientific BoardApril 18, 2024 | finance.yahoo.comRenovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient CareMarch 12, 2024 | markets.businessinsider.comONGOING INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RenovaroMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENBMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…March 10, 2024 | markets.businessinsider.comINVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RenovaroMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENBFebruary 28, 2024 | stockhouse.comRenovaro Shareholder NoticeFebruary 26, 2024 | stockhouse.comRenovaro Shareholder AlertFebruary 25, 2024 | prnewswire.comROSEN, LEADING INVESTOR COUNSEL, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENBFebruary 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENBFebruary 23, 2024 | finance.yahoo.comRENB Apr 2024 2.500 callFebruary 22, 2024 | investorplace.comRed Flag Alert: 3 Stocks That Hindenburg Research Is Shorting NowFebruary 18, 2024 | markets.businessinsider.comRenovaro Ongoing Investor AlertFebruary 17, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENBFebruary 16, 2024 | prnewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENBFebruary 15, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENBFebruary 15, 2024 | globenewswire.comCutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplaceFebruary 14, 2024 | sg.finance.yahoo.comHit With Short Seller Report, Renovaro Biosciences Comments On Hindenburg's Opinion PieceFebruary 14, 2024 | msn.comRenovaro Biosciences soars after responding to Hindenburg short callFebruary 14, 2024 | finanznachrichten.deRenovaro Biosciences Inc.: Statement of Renovaro IncFebruary 14, 2024 | finance.yahoo.comStatement of Renovaro IncFebruary 14, 2024 | globenewswire.comStatement of Renovaro IncSee More Headlines Receive RENB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renovaro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today5/09/2024Next Earnings (Estimated)5/10/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RENB CUSIPN/A CIK1527728 Webwww.enochianbio.com Phone305-918-1980FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.25% Return on Assets-65.29% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book1.57Miscellaneous Outstanding Shares143,668,000Free Float112,463,000Market Cap$180.30 million OptionableOptionable Beta0.44 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesHon. Mark R. Dybul M.D. (Age 60)CEO, Director & Member of HBV Scientific Advisory Board Comp: $764.58kDr. Francois Binette M.Sc. (Age 60)Ph.D., COO and Executive VP for Research & Development Comp: $504.38kDr. Serhat GümrükcüCo-Founder & InventorMr. Simon Tarsh (Age 62)Interim Chief Financial Officer Mr. Greg Duczynski Ph.D.Senior Vice President for Clinical OperationsKey CompetitorsOmerosNASDAQ:OMEROvid TherapeuticsNASDAQ:OVIDAcrivon TherapeuticsNASDAQ:ACRVMerrimack PharmaceuticalsNASDAQ:MACKTrevi TherapeuticsNASDAQ:TRVIView All CompetitorsInstitutional OwnershipSG Americas Securities LLCBought 17,263 shares on 5/7/2024Ownership: 0.012%View All Institutional Transactions RENB Stock Analysis - Frequently Asked Questions How have RENB shares performed in 2024? Renovaro's stock was trading at $3.17 at the start of the year. Since then, RENB shares have decreased by 60.6% and is now trading at $1.25. View the best growth stocks for 2024 here. Are investors shorting Renovaro? Renovaro saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,320,000 shares, an increase of 90.2% from the March 15th total of 1,220,000 shares. Based on an average trading volume of 295,300 shares, the short-interest ratio is currently 7.9 days. Currently, 2.3% of the shares of the company are short sold. View Renovaro's Short Interest. When is Renovaro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our RENB earnings forecast. How were Renovaro's earnings last quarter? Renovaro Inc. (NASDAQ:RENB) posted its earnings results on Wednesday, February, 14th. The company reported ($0.07) earnings per share for the quarter. What ETF holds Renovaro's stock? Amplify Treatments, Testing and Advancements ETF holds 33,976 shares of RENB stock, representing 0.50% of its portfolio. Who are Renovaro's major shareholders? Renovaro's stock is owned by many different retail and institutional investors. Top institutional investors include SG Americas Securities LLC (0.01%). How do I buy shares of Renovaro? Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RENB) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange348 million Americans lives to END as we know it?The Oxford ClubThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
